Effect of Biofield Energy Treatment on Streptococcus group B: A Postpartum Pathogen

What is it about?

Streptococcus agalactiae group B (S. agalactiae gr. B) is widespread in nature mainly causes bacterial septicemia and neonatal meningitis. The current study was attempted to investigate the effect of biofield treatment on S. agalactiae gr. B with respect of antimicrobial sensitivity, biochemical reactions and bio typing. S. agalactiae gr. B strain was used in this experiment bearing the American Type Culture Collection (ATCC 12386) number and stored according to the recommended storage protocol. The revived and lyophilized state of ATCC strains of S. agalactiae gr. B were selected for the study. Gr. I was considered as control. Both revived (Group; Gr. II) and lyophilized (Gr. III) strains of S. agalactiae gr. B were subjected to Mr. Trivedi’s biofield treatment. Gr. II was assessed on day 5 and day 10 while Gr. III on day 10 with respect to the control (Gr. I) using MicroScan Walk-Away® system. Although biofield treatment did not show any change with respect to susceptibility pattern. However the minimum inhibitory concentration of S. agalactiae gr. B showed significant (70.37%) alteration, out of twenty-seven tested antimicrobials, among which in Gr. II i.e. 62.96% on day 5 and 66.67% on day 10 while no alteration was found in lyophilized group (Gr. III) as compared to the control. Moreover, the improvement of MIC value of norfloxacin was observed by two-fold (8 to ≤4 µg/mL) in Gr. II on day 10 after biofield energy treatment as compared to the control. It was observed that overall 48.28% biochemical reactions, out of twenty-nine were altered in Gr. II with respect to the control. Moreover, biotype numbers were changed in Gr. II on day 5 (777777615) and on day 10 (757677405) as compared to the control (237147047). The results suggest that biofield treatment has significant impact on S. agalactiae gr. B in revived treated cells (Gr. II) with respect to MIC values, biochemical reactions pattern and biotype number.

Featured Image

Why is it important?

Group B Streptococci (GBS), or Streptococcus agalactiae group B, are Gram-positive, non-spore forming, non-motile, β-hemolytic and chain-forming cocci bacteria. It is mainly inhabitant in human gut flora and female urogenital tract [1]. Pregnant women [2] and neonates [3] are the main victim host of this organism. It can be transferred to neonates through the birth canal and causes bacterial septicaemia and neonatal meningitis [4]. Most of GBS, produce Christie-Atkins-Munch-Petersen (CAMP) factor or protein B an extracellular cytolytic protein and β-lysin from Staphyllococcus species are jointly lysed the erythrocytes [5]. It is estimated that in US over 70,000 cases of GBS diseases were prevented [6]. Several antibiotics such as penicillin, ampicillin, amoxicillin, cephalosporins (all three generations), macrolides, clindamycin and vancomycin (as alternative) have been used to treat against GBS infections. Among above mentioned antibiotics penicillin is the drug of choice next to cefazolin. However, it also have certain limitations such as high minimum inhibitory concentration (MIC), a factor associated with high level of bacteremia and more concentration of microbes in tissue, especially in cerebrospinal fluid [7,8]. Therefore, some alternative treatment strategies are needed to overcome these lacunas against β-hemolytic strain of gr. B Streptococci. Biofield treatment has been known as an alternative approach that may be useful for S. agalactiae group B infected patients. Researchers have shown that short-lived electrical events or action potential exist in the several type of mammalian cells such as neurons, muscles, and endocrine cells [9]. For instance, when the cells present in central nervous system of human body communicate with each another by means of electrical signals that propagate along the nerve impulses. Therefore, it was hypothesized that biofield exists around the human body and evidence was found using electromyography, electrocardiography and electroencephalogram [10]. Thus, the human body emits the electromagnetic waves in the form of bio-photons, which surrounds the body and it is commonly known as biofield. Therefore, the biofield consists of electromagnetic field, being generated by moving electrically charged particles (ions, cell, molecule etc.) inside the human body. Rivera-Ruiz reported that electrocardiography has been extensively used to measure the biofield of human body [11]. Thus, human has the ability to harness the energy from environment or Universe and can transmit into any living or nonliving object(s) around the Globe. The objects always receive the energy and responding into useful way that is called biofield energy and the process is known as biofield treatment that is also called as Trivedi effect®. Mr. Trivedi’s unique biofield treatment has been known to transform the structural, physical, and thermal properties of several metals in material science [12-14], improved the overall productivity of crops [15,16], altered characteristics features of microbes [17-19] and improved growth and anatomical characteristics of various medicinal plants [20,21]. Due to the clinical significance of this organism and literature reports on biofield treatment, the present work was undertaken to evaluate the impact of biofield treatment on S. agalactiae group B in relation to antimicrobials susceptibility and bio typing based on various biochemical characters.

Perspectives